Nanobac Pharmaceuticals, Inc. - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Nanobac Pharmaceuticals, Inc.. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Nanobac Pharmaceuticals, Inc.. The Group's principal activity is the research and development of therapeutic and diagnostic technologies relating to the pleomorphic pathogen known as nanobacterium sanguineum. The Group is biolifescience company which develops diagnostic tests for the detection of Nanobacterial infection, as well as medications that treat atherosclerosis and coronary heart disease. It has a commercially available serology test for the identification of nanobacterial antibodies and antigens. It also conducts biomedical research and clinical studies in the development of atherosclerosis, gall stones, chronic prostatitis, diabetes, arthritic spurs, cataracts, scleroderma, kidney cysts and kidney stones, certain breast pathology, polycystic kidney disease, solid tumor pathologies, immunosuppressed conditions, dental pulp stone, and neurodegenerative disease. It majorly operates in the United States and Finland.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report